To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate a safe treatment interruption interval(s) for
re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to
10 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Solvay Pharmaceuticals
Collaborators:
H. Lundbeck A/S Wyeth is now a wholly owned subsidiary of Pfizer